“Increased Risk of COVID-19 in Cancer Patients with Lung Diseases Treated with Immune Checkpoint Inhibitors during Omicron Outbreak in China: A Retrospective Study”

[Pubmed Link](https://pubmed.ncbi.nlm.nih.gov/38093559)

This study found a higher risk of coronavirus disease 2019 (COVID-19) in cancer patients with lung diseases who received immune checkpoint inhibitors during the Omicron outbreak in China.